A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
Latest Information Update: 30 Jan 2023
At a glance
- Drugs Selinexor (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms KING
- Sponsors Karyopharm Therapeutics
- 02 Nov 2021 Results assessing intra-tumoral penetration, safety, and efficacy of selinexor monotherapy for recurrent glioblastoma published in the Clinical Cancer Research
- 30 Jul 2021 Status changed from completed to discontinued.
- 03 Nov 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.